Buruli Ulcer (BU) is a cutaneous disease caused by Mycobacterium ulcerans. The 17 pathogenesis of this disease is closely related to the secretion of the toxin mycolactone that 18 induces extensive destruction of the skin and soft tissues. Although the World Health Organization 19 recommends a combination of rifampicin and streptomycin for the treatment of BU, clinical 20 management of advanced stages often requires extensive surgical resection of the infected 21 tissue. Therefore, it is important to develop alternative strategies for the treatment of BU. 22 Endolysins (lysins) are phage encoded enzymes that degrade peptidoglycan of bacterial 23 cell walls. Over the past years, lysins have been emerging as alternative antimicrobial agents 24 against Gram-positive bacteria. Amongst Gram-positive bacteria, mycobacteria have an unusual 25 outer membrane that is covalently attached to the mycolylarabinogalactan-peptidoglycan 26 complex. To overcome this additional barrier to phage-mediated lysis, some mycobacteriophages 27 encode a lipolytic enzyme, Lysin B (Lys B).
INTRODUCTION
Buruli ulcer (BU) is a necrotic cutaneous disease caused by Mycobacterium ulcerans and represents the third most prevalent mycobacterial infection worldwide, after tuberculosis and 1.0 and clumps were dispersed by passing the bacterial suspension several times through a 25medium. A stock solution of purified Lys B was serially diluted in phosphate buffer (final
Treatment of M. ulcerans-infected mice with Lys B 151
The treatment was initiated when footpads of mice were swollen to 2.7 mm and was The levels of the cytokines tumor necrosis factor (TNF) and gamma interferon (IFN-γ) in 172 the supernatant of homogenized suspensions from DLN of mice were quantified by using a polystyrene microtitre plates (Nunc) were coated with Lys B (10 µg/ml) and incubated overnight at 4ºC. The wells were blocked with 0.05% (v/v) Tween 20 in PBS for 1h at room temperature.
Lys B shows in vitro antimicrobial activity against M. ulcerans isolates
To investigate the efficacy of Lys B treatment for the control of M. ulcerans in vivo, we
The RIF/STR regimen recommended by the WHO for the treatment of BU is often not effective in advanced ulcerative stages of the disease, for which the adjunction of surgical treatment in advanced stages of the disease. 
